The Treatment of Hormone-Refractory Prostate Cancer: Docetaxel and Beyond

Reviews in Urology

Daniel P Petrylak¹ 

[1] Division of Oncology, Department of Medicine, Columbia University Medical Center, New York, NY

关键词: Prostate cancer;    Androgen ablation;    Prostate-specific antigen;    Estramustine;    Docetaxel;    Endothelin receptor antagonist;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

Two randomized clinical trials demonstrated a survival benefit of 20% to 24% with docetaxel-based therapy when compared with survival with mitoxantrone and prednisone after failure of androgen ablation therapy. These studies supported the approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer by the US Food and Drug Administration in May 2005. Clinical trials in hormone-refractory prostate cancer are now focused on building on the survival improvement seen with docetaxel-based therapy. This article presents a summary of some of the more promising treatments and regimens for advanced prostate cancer.

【 授权许可】

Unknown